Canaccord Genuity Sees GenMark Diagnostics (GNMK) Trading Above Buyout Comps, PT Raised to $24

February 16, 2021 8:52 AM EST
Get Alerts GNMK Hot Sheet
Price: $24.01 +0.08%

Rating Summary:
    2 Buy, 6 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Canaccord Genuity analyst Max Masucci raised the price target on GenMark Diagnostics (NASDAQ: GNMK) to $24.00 (from $22.00) using history to understand the buyout speculation. Two comparable deals, bioMérieux’s acquisition of BioFire and Danaher’s acquisition of Cepheid both took place at 5.6x forward revenue. In a normalized environment, the analyst believes the company could report $210M, up from the $181M currently modeled.

The analyst maintained the Buy rating but noted "If we apply the estimated $210.5M in revenues GNMK may generate in 2021, the company’s EV/Sales multiple stands at ~7.5x, or +33% above the ~5.6x forward multiples Cepheid and BioFire commanded 7 and 4 years ago".



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Hot Comments, Rumors

Related Entities

Canaccord Genuity, Definitive Agreement